Darlifarnib+cabozantinib在肾癌和头部/颈部癌症中表现出强烈反应, Kura于2025年10月18日主办了一次投资者活动。 Darlifarnib plus cabozantinib showed strong response in kidney and head/neck cancers, with Kura hosting an investor event on October 18, 2025.

库尔库尔肿瘤学在2025年ESMO大会上介绍了FTI方案的初步数据,表明darlifarnib和cabozantinib在高级肾脏细胞癌患者(包括以前用cabozantinib治疗的患者)中实现了50%的客观反应率和80%的疾病控制率。 Kura Oncology presented preliminary data from its FTI programs at the 2025 ESMO Congress, showing that darlifarnib combined with cabozantinib achieved a 50% objective response rate and 80% disease control rate in advanced renal cell carcinoma patients, including those previously treated with cabozantinib. 在人体免疫机能丧失综合症(HRAS)的混合固态肿瘤中,darlifarnib显示具有可控安全特征的抗突触活性。 In HRAS-mutant solid tumors, darlifarnib showed antitumor activity with a manageable safety profile. 与单独使用 alpelisib 没有反应相比，tipifarnib-alpelisib 组合在 PIK3CA 改变的头颈部鳞状细胞癌患者中产生了 47% 的缓解率。 The tipifarnib-alpelisib combination produced a 47% response rate in PIK3CA-altered head and neck squamous cell carcinoma patients, compared to no response with alpelisib alone. 这些结果表明FTIs可能克服针对性治疗的耐药性. These results suggest FTIs may overcome resistance to targeted therapies. Kura计划于2025年10月18日举办虚拟投资者活动, Kura plans a virtual investor event on October 18, 2025, to discuss the findings.